Patents Assigned to TAKIS S.R.L.
  • Immunotherapy against ErbB-3 receptor
    Patent number: 10745459
    Abstract: The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: August 18, 2020
    Assignee: TAKIS S.R.L.
    Inventors: Luigi Aurisicchio, Gennaro Ciliberto, Rita Mancini, Emanuele Marra, Guiseppe Roscilli
  • Immunotherapy against ErbB-3 receptor
    Patent number: 9688738
    Abstract: The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: June 27, 2017
    Assignee: TAKIS S.R.L.
    Inventors: Luigi Aurisicchio, Gennaro Ciliberto, Rita Mancini, Emanuele Marra, Guiseppe Roscilli
  • IMMUNOTHERAPY AGAINST ERBB-3 RECEPTOR
    Publication number: 20140017259
    Abstract: The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.
    Type: Application
    Filed: November 2, 2011
    Publication date: January 16, 2014
    Applicant: TAKIS S.R.L.
    Inventors: Luigi Aurisicchio, Gennaro Ciliberto, Rita Mancini, Emanuele Marra, Guiseppe Roscilli